Chong EA et al. BTK inhibitors in cancer patients with COVID19: "The winner will be the one who controls that chaos" (Napoleon Bonaparte). Clin Cancer Res 2020;[Online ahead of print]. Abstract

Jin XH et al. COVID-19 in a patient with chronic lymphocytic leukaemia. Lancet Haematol 2020;7(4):e351-2. Abstract

Koffman B et al. Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. Am J Hematol 2020;[Online ahead of print]. Abstract

Lawrence L. Patient with CLL may have had longer COVID-19 incubation period. https://www.cancertherapyadvisor.com/home/cancer-topics/chronic-lymphocytic-leukemia/chronic-leukemia-cll-patients-coronavirus-covid19-longer-incubation/. Accessed June 1, 2020.

Mahmoudjafari Z et al. American Society for Transplantation and Cellular Therapy pharmacy special interest group position statement on pharmacy practice management and clinical management for COVID-19 in hematopoietic cell transplant and cellular therapy patients in the United States. Biol Blood Marrow Transplant 2020;26(6):1043-9. Abstract

Paneesha S et al Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia. Leuk Res 2020;[Online ahead of print]. Abstract  

Perini GF et al. How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: A Brazilian task force recommendation. Hematol Transfus Cell Ther 2020;[Online ahead of print]. Abstract

Shadman M et al. COVID-19 and CLL: Frequently Asked Questions. https://www.hematology.org/covid-19/covid-19-and-cll. Accessed June 1, 2020.

Treon SP et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood 2020;135(21):1912-5. Abstract